Carl Schmid commented on the JAMA Viewpoint piece “Subscription-Based Pricing for Lenacapavir—Learning From Hepatitis C and Cabotegravir,” taking issue with the authors’ dismissal of advocates focus on insurer’s responsibility to follow the law and cover PrEP as a no cost preventive service and offering comments on the hepatitis C subscription model and the need for a comprehensive PrEP program to increase uptake.
We strongly support NJ Assembly Bill 5217 which ensures that health insurers accept and count payments made on behalf of patients toward their deductibles and out-of-pocket maximums. We respectfully urge Gov. Phil Murphy to sign Assembly Bill 5217 into law.
We strongly support NJ Senate Bill 3818/Assembly Bill 5217 which ensures that health insurers accept and count payments made on behalf of patients toward their deductibles and out-of-pocket maximums.
We joined with the Arthritis Foundation on a letter signed by 20 patient groups to HHS Secretary Robert F. Kennedy Jr. and CMS Administrator Dr. Oz regarding TrumpRx, thanking them for their efforts for lowering Rx costs, but highlighting the need to ensure that patients are aware that their costs do not count towards their insurance requirements and cost-sharing.
As a national patient advocacy organization that works to promote quality and affordable healthcare for individuals living with or at risk of HIV, hepatitis, and other chronic conditions, we see firsthand how PBM practices, pharmacy access, and insurance design determine whether patients can remain on lifesaving treatment. We appreciate the Board’s continued focus on practical, patient-centered reforms that Oregon can move forward with.